ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery

How One Tiny Molecule Turned into One Huge Health Breakthrough

Nutrients Boost Stem Cell Function

Humans have three times more brown body fat

B12 Proven Essential for Every Cell

Soy isoflavones may benefit breast cancer patients

How B Vitamins Improve Brain Health, Cognition, Psychiatric Problems and Mood Disorders

Dietary prebiotics improve sleep, buffer impacts of stress, says study

Ylang Ylang Oil Not Only Soothes Your Skin, but Your Mind as Well

Exercises to Help Prevent Urinary Incontinence

 
Print Page
Email Article

New Treatment Choice for People with Manic Depression

  [ 651 votes ]   [ Discuss This Article ]
www.ProHealth.com • May 21, 2003


Alderley Park, UK – Important developments in the treatment of manic depression were presented for the first time today at the American Psychiatric Association's (APA) annual meeting, the largest psychiatric congress in the world, which indicate that Seroquel (quetiapine) is an effective, well tolerated and fast-acting treatment for the manic symptoms of manic depression.(1)

Quetiapine, a new generation antipsychotic manufactured by AstraZeneca, is currently prescribed by psychiatrists to treat schizophrenia. Today's findings indicate that when prescribed on its own, quetiapine (monotherapy) can also be an effective treatment for the millions of people worldwide who have manic depression. The results, based on trial data from more than 400 patients, found quetipaine to be statistically more effective at treating the manic symptoms of manic depression than placebo, fast-acting as symptom improvements were evident from day four and well tolerated by patients.

Manic depression, also known as bipolar disorder, is a serious mental illness that affects approximately 3-4% of the adult population and is the sixth leading cause of disability in the world. (2,3,4,5) One of the issues faced by psychiatrists treating this condition is the problems associated with treatment compliance due to tolerability issues with some treatments. More than half of those with bipolar disorder stop taking their medication at some point during their lives, subjecting themselves to a high risk of relapse and an increased risk of suicide.(6)

"The results of these studies are an exciting development in the psychiatry field. The patients on quetiapine in these trials responded extremely well, not only was the improvement in their condition significant but it was also rapid" commented Dr. Eduard Vieta, Director of Research, Department of Psychiatry, University of Barcelona. "Effectively controlling this condition can be problematic as the occurrence of side effects, such as movement disorders, weight gain and sexual dysfunction, caused by some medications may lead to patients discontinuing their medication.

Patients with bipolar disorder can now look forward to receiving a treatment that not only controls their symptoms but does not create compliance issues due to side effects. Therefore, on the basis of today's results, psychiatrists will now be able to consider quetiapine as a first-line treatment for this condition."

The results presented today were from two clinical trials undertaken as part of a large comprehensive trial programme involving almost 1,000 patients in 28 countries which studied the efficacy, tolerability and safety of quetiapine in bipolar disorder as monotherapy and as adjunctive therapy with standard mood stabilising medication. The results of these studies were submitted to the US Food and Drug Administration and European regulatory body earlier this year to obtain a licence for use of Seroquel in bipolar disorder.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

In Neuroscience, AstraZeneca is dedicated to providing medicines that have the potential to change patients' lives. The company already markets several products including SEROQUEL®, one of the fastest growing global antipsychotics with proven efficacy and a very favourable side effect profile; and ZOMIG®, a reliable migraine therapy and a leader within the triptan market. The Neuroscience pipeline includes leading approaches for the treatment of depression and anxiety, overactive bladder, dementia and stroke, pain control and anaesthesia.


'Seroquel' is a trademark of AstraZeneca

YMRS (Young Mania Rating Scale) is an 11-item instrument used to assess the severity of mania.



This psychiatry resource features educational materials relating to severe mental illness, including background information on schizophrenia as well as epidemiological data and treatment issues clinicians face in everyday practice.

References:

1. Jones MW, Huizar K, et al. Quetiapine monotherapy for mania associated with bipolar disorder. Poster presented at 156th American Psychiatric Association Congress, San Francisco, 2003.

2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington DC, American Psychiatric Association, 2000: p.385, 395.

3. Hirschfield et al. Journal of Clinical Psychiatry 2003 (January); 64:53-59.

4. Lisd JD, Dime-Meenan S, Whybrow PC et al. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord, 1994, 31: 281 – 294.

5. World Health Organization and the World Bank. The Global Burden of Disease: Summary. Cambridge, Mass: The Harvard School of Public Health Harvard University Press, 1996.

6. Miklowitz D. The Bipolar Disorder Survival Guide. New York: The Guilford Press, 2002.



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Mitochondria Ignite™ with NT Factor® Optimized Curcumin Longvida®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Vital Molecule Increases Cellular Energy and Improves Cognitive Function Vital Molecule Increases Cellular Energy and Improves Cognitive Function
Optimize Your Immune System Naturally: Thymic Protein A Optimize Your Immune System Naturally: Thymic Protein A
Vitamin K-2 – A Key Player in Cardiovascular and Bone Health Vitamin K-2 – A Key Player in Cardiovascular and Bone Health
How One Tiny Molecule Turned into One Huge Health Breakthrough How One Tiny Molecule Turned into One Huge Health Breakthrough
The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map